Ascendis Pharma A/S
ASND
$223.82
-$3.59-1.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 110.17% | 103.22% | 55.68% | 10.59% | 35.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 110.17% | 103.22% | 55.68% | 10.59% | 35.98% |
| Cost of Revenue | 125.28% | 76.90% | 64.27% | 13.18% | -0.41% |
| Gross Profit | 108.07% | 107.92% | 54.24% | 10.16% | 43.26% |
| SG&A Expenses | 66.21% | 49.77% | 34.44% | 21.41% | 10.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.76% | 25.82% | 11.63% | 0.59% | -11.10% |
| Operating Income | 49.09% | 54.31% | 27.92% | 8.49% | 38.61% |
| Income Before Tax | 41.61% | 45.80% | 45.02% | 32.06% | 21.15% |
| Income Tax Expenses | 237.23% | 5.28% | -21.63% | -60.39% | -33.24% |
| Earnings from Continuing Operations | 38.04% | 44.66% | 44.59% | 32.53% | 21.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 38.04% | 44.66% | 44.59% | 32.53% | 21.33% |
| EBIT | 49.09% | 54.31% | 27.92% | 8.49% | 38.61% |
| EBITDA | 51.80% | 56.86% | 28.98% | 8.55% | 39.73% |
| EPS Basic | 41.10% | 47.57% | 46.82% | 34.74% | 22.97% |
| Normalized Basic EPS | 42.44% | 48.64% | 47.22% | 34.27% | 22.80% |
| EPS Diluted | 41.11% | 47.57% | 46.81% | 34.73% | 22.97% |
| Normalized Diluted EPS | 41.99% | 48.33% | 46.93% | 35.50% | 24.07% |
| Average Basic Shares Outstanding | 4.62% | 5.56% | 4.73% | 3.87% | 2.85% |
| Average Diluted Shares Outstanding | 4.55% | 5.47% | 4.66% | 5.40% | 4.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |